Thomas K. H. Chang

Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes.

Thomas K. H. Chang, Georg F. Weber, Charles L. Crespi et al. · PubMed · 1993 · 550 citations

Anticancer Drug Cyclophosphamide, Redox Biology, Toxicological Mechanism +21

NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models

Deborah H. Charych, Ute Hoch, John L. Langowski et al. · Clinical Cancer Research · 2016 · 385 citations

Evaluation of Triacetyloleandomycin, α-Nasymphthoflavone and Diethyldithiocarbamate as Selective Chemical Probes for Inhibition of Human Cytochromes P450

Thomas K. H. Chang, Frank J. Gonzalez, David J. Waxman · Archives of Biochemistry and Biophysics · 1994 · 253 citations

Molecular Pharmacology, Medicinal Chemistry, Pharmaceutical Science +12

Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation.

Erin Code, Charles L. Crespi, Bruce W. Penman et al. · PubMed · 1997 · 246 citations

Molecular Pharmacology, Aflatoxin B1, Substrate Specificity +21

Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: Regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes

Arleen B. Rifkind, Charis A. Lee, Thomas K. H. Chang et al. · Archives of Biochemistry and Biophysics · 1995 · 245 citations · Full text